Cue Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. (CUE) on April 11, 2023. The report discloses a corporate governance event involving the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
On April 11, 2023, Patrick Verheyen was appointed to the Board of Directors following a recommendation by the Corporate Governance and Nominating Committee. No other material changes to financial operations or strategy were reported in this document.
Compensation and Governance Details
- Appointment: Patrick Verheyen joined the Board on April 11, 2023.
- Equity Grant: Upon appointment, Mr. Verheyen received an option to purchase 40,000 shares of common stock.
- Vesting Schedule: The option vests over three years, with one-third vesting on the one-year anniversary and the remainder in eight equal quarterly installments.
- Indemnification: Mr. Verheyen entered into the Company's standard indemnification agreement, covering expenses such as legal fees and judgments arising from his service.
- Policy Reference: Compensation is governed by the Director Compensation Policy dated March 31, 2023.
Investor Verification Checklist
- Verify the full text of the Director Compensation Policy (Exhibit 10.1) to understand total potential director compensation.
- Review the Company's most recent Form 10-K for current financial health, cash runway, and debt levels, as this 8-K contains no financial data.
- Confirm the vesting terms and exercise price of the 40,000 share option granted to Mr. Verheyen.
- Assess the strategic rationale for appointing Mr. Verheyen based on his professional background.